Understanding patient needs in switching from biologic to biosimilar medicines: Final report of survey and focus group findings – The Patients Association

Patients Association report that finds patients with common conditions such as rheumatoid arthritis, psoriasis and ulcerative colitis are being switched to new medicines without receiving the support they need to understand any changes, or to monitor and manage side effects

Cannabis-based medicines: an interim desktop guide – Royal College of General Practitioners

Report from the Royal College of General Practitioners giving an overview of the current legal situation regarding medicinal cannabis, the different forms it is available in, the conditions for which there is some, if limited, clinical evidence of benefit, and

The 2019 Voluntary Scheme For Branded Medicines Pricing And Access: Chapters And Glossary – Department of Health and Social Care

The voluntary scheme for branded medicines pricing and access is a non-contractual voluntary agreement between the Department of Health and Social Care (DHSC) and the Association of the British Pharmaceutical Industry (ABPI).  DHSC is acting on behalf of the UK government,

NHS Urgent Medicine Supply Advanced Service (NUMSAS) Training Module – NHS England

A training module developed for NHS 111 health advisors and pharmacy teams to help describe the NHS Urgent Medicine Supply Advanced Service (NUMSAS) and to illustrate the change in the patient journey since its introduction.

English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2018 – Public Health England

Fifth annual report of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR), which was established in 2013 to support Public Health England (PHE) in the delivery of the UK Five Year Antimicrobial Resistance Strategy 2013 to 2018. It

From Patent to Patient: Analysing access to innovative cancer drugs – Institute of Cancer Research

Report that looks at how to best harness advances in science to bring innovative drugs to patients. It is designed to help us reshape the landscape for drug discovery and development – and create tomorrow’s cancer treatments.

2018/19 Community Pharmacy Contractual Framework (CPCF) National Clinical Audit: Flu Vaccination for People with Diabetes – NHS England

This guidance document provide information on the 2018/19 Community Pharmacy Contractual Framework National Audit, which is focused on the provision of seasonal influenza vaccination to people with diabetes.

Quality Payments: Guidance for the February 2019 Review Point – NHS England

This guidance document sets out the requirements in order to participate in the Community Pharmacy Quality Payments Scheme. The Scheme will reward community pharmacies for delivering quality criteria in all three of the quality dimensions: Clinical Effectiveness, Patient Safety and

Innovation in AMR: patent trends for novel diagnostics – Nesta

Research into patents and connected patent families using keywords relevant to point-of-care (POC) diagnostic tests for addressing antimicrobial resistance. This research analysed what patents are being filed and therefore what technology is being developed. The report assesses the implications on

Supplementary information on cannabis-based products for medicinal use – NHS England NHS England

This further letter has been issued which provides additional guidance to clinicians and organisations following the rescheduling of cannabis-based products for medicinal use. This clarifies the status of the clinical guidance issued, and provides further clarification in relation to synthetic

Cannabis-based products for medicinal use – NHS England

Following the Government’s announcement to reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians following the re-scheduling which sets out our expectations of what this regulatory change will mean in practice for clinicians working in

Ensuring access to medicines: How to stimulate innovation to meet patients’ needs?: (Policy Brief 29) – European Observatory on Health Systems and Policies

Brief that aims to inform discussions about stimulating more meaningful productivity in terms of pharmaceutical R&D. More specifically, it explores how R&D efforts can be steered to areas of unmet clinical needs and how efficiency in the R&D process can

Interim protocol on dispensing of adrenaline auto-injectors, 150microgram – NHS England

This guidance on the dispensing of adrenaline auto-injectors (150microgram) has been developed for pharmacies and dispensing GP practices. This validation protocol has been developed to ensure consistent practice nationally and to prevent the need for any local re-interpretation.

Antimicrobial resistance: Eleventh Report of Session 2017–19: Report, together with formal minutes relating to the report – House of Commons Health and Social Care Committee

House of Commons Health and Social Care Committee report that identifies that tackling antimicrobial resistance needs to be firmly established as a ‘top five policy priority’ for the government in order to help prevent the virtual loss of worldwide modern

Junior Epipen shortage: letter to parents and guardians from Dr Aidan Fowler, National Director of Patient Safety – NHS England

Experts in children’s allergies have developed the advice in this letter to support parents and guardians of children who use Epipen Junior 150mcg.

Burosumab for treating X-linked hypophosphataemia in children and young people: Highly specialised technologies guidance [HST8] – NICE

Evidence-based recommendations on burosumab (Crysvita) for X‑linked hypophosphataemia in children and young people. Burosumab is recommended, within its marketing authorisation, for treating X‑linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in

Cabozantinib for untreated advanced renal cell carcinoma: Technology appraisal guidance [TA542] – NICE

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults. Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate‑ or poor‑risk as defined in the International Metastatic Renal

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs: Technology appraisal guidance [TA543] – NICE

Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs. It recommends:  Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as